Wecome Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.67%

Wecome Pharmaceutical Co Ltd (300878) has an Asset Resilience Ratio of 0.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Wecome Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥10.00 Million

≈ $1.46 Million USD Cash + Short-term Investments

Total Assets

CN¥1.49 Billion

≈ $217.74 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2023)

This chart shows how Wecome Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 300878 net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Wecome Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Wecome Pharmaceutical Co Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥10.00 Million	0.67%
Total Liquid Assets	CN¥10.00 Million	0.67%

Asset Resilience Insights

Limited Liquidity: Wecome Pharmaceutical Co Ltd maintains only 0.67% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Wecome Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wecome Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Wecome Pharmaceutical Co Ltd (2023–2023)

The table below shows the annual Asset Resilience Ratio data for Wecome Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	12.00%	CN¥245.56 Million ≈ $35.93 Million	CN¥2.05 Billion ≈ $299.49 Million	--

pp = percentage points

About Wecome Pharmaceutical Co Ltd

SHE:300878 China Biotechnology

Market Cap

$605.54 Million

CN¥4.14 Billion CNY

Market Cap Rank

#11558 Global

#3518 in China

Share Price

CN¥28.58

Change (1 day)

+3.93%

52-Week Range

CN¥14.81 - CN¥35.33

All Time High

CN¥52.21